Vigabatrin and Insulin Sensitivity

Obesity Clinical Trial

Official title: The Effect of Vigabatrin on Insulin Sensitivity

Status Recruiting

Clinical Trial Summary

Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity and is associated with an increased risk of developing type 2 diabetes. The hallmark feature of NAFLD is an increase in intrahepatic triglyceride (IHTG) content. Data from studies conducted in rodent models suggest increased IHTG content can alter hepatic vagal afferent nerve (HVAN) activity. In rodent models of obesity and NAFLD, HVAN activity is reduced leading to impaired insulin sensitivity and glucose control. The reduction in HVAN activity is likely due to increased hepatic release of GABA, an inhibitory neurotransmitter, attributable to increased expression of GABA-Transaminase (GABA-T). Pharmacological inhibition of GABA-T in obese mice by treatment with vigabatrin, an irreversible inhibitor of GABA-T improves glucose tolerance and reduces hyperinsulinemia, hyperglycemia, and insulin resistance. It is not known if vigabatrin can also improve metabolic function in people. We propose to conduct a 3-week, single-arm trial to assess the effect size of treatment with vigabatrin on the following specific aims with the larger goal of determining whether a large, randomized controlled trial investigating the effect of vigabatrin is warranted.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Insulin Resistance
• NAFLD
• Obesity

• NCT number: NCT04321395
• Study type: Interventional
• Source: Washington University School of Medicine
• Contact: Sarah S Farabi, PhD
• Phone: 3143628554
• Email: ssfarabi@wustl.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: August 23, 2021
• Completion date: December 2023